Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body’s peripheral nervous system. The company’s lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.